Print（PDF/122KB） Apr. 04, 2025 Finances

Sumitomo Pharma Announces Reduction in Executive Remuneration

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura; Securities Code: 4506, Prime Market of TSE) announced today that, although the Company is in the process of recovering from financial difficulties, the Company continues to face a challenging business situation and in light of the dividend forecasts for the fiscal year ended March 31, 2025 (no dividend), the Company will extend the period of reduced remuneration for the its Directors as below.

1. Scope of reduction:

Representative Director, President and CEO	30% of base remuneration
Other Directors (excluding Outside Directors)	20% of base remuneration
Performance-linked remuneration (bonuses) for the year ended March 31, 2025 will be reduced by 100% for all eligible Directors.

2. Period of reduction of the base remuneration:

From April 2025 to June 2025

* The same amount of reduction implemented from May 2024 to March 2025 will be extended for three months.